18F-FDG PET/CT for Monitoring Response of Merkel Cell Carcinoma to the Novel Programmed Cell Death Ligand 1 Inhibitor Avelumab.
Publication
, Journal Article
Eshghi, N; Lundeen, TF; MacKinnon, L; Avery, R; Kuo, PH
Published in: Clin Nucl Med
May 2018
An 85-year-old man with stage IIIA Merkel cell carcinoma of the left arm was initially treated with local excision and axillary node dissection followed by radiation therapy. Eight months after surgery, whole-body FDG PET/CT demonstrated intensely hypermetabolic hepatic metastases and abdominal lymphadenopathy. Given his age and comorbidities, he was considered a poor candidate for chemotherapy, and therefore the novel programmed cell death ligand 1 inhibitor avelumab was initiated. FDG PET/CT after 4 cycles showed complete resolution of hepatic and nodal metastases. Whole-body FDG PET/CT can be used for monitoring response of multisystem metastases from Merkel cell carcinoma to active immunotherapy.
Duke Scholars
Published In
Clin Nucl Med
DOI
EISSN
1536-0229
Publication Date
May 2018
Volume
43
Issue
5
Start / End Page
e142 / e144
Location
United States
Related Subject Headings
- Skin Neoplasms
- Radiopharmaceuticals
- Positron Emission Tomography Computed Tomography
- Nuclear Medicine & Medical Imaging
- Male
- Humans
- Fluorodeoxyglucose F18
- Carcinoma, Merkel Cell
- Antineoplastic Agents
- Antibodies, Monoclonal, Humanized
Citation
APA
Chicago
ICMJE
MLA
NLM
Eshghi, N., Lundeen, T. F., MacKinnon, L., Avery, R., & Kuo, P. H. (2018). 18F-FDG PET/CT for Monitoring Response of Merkel Cell Carcinoma to the Novel Programmed Cell Death Ligand 1 Inhibitor Avelumab. Clin Nucl Med, 43(5), e142–e144. https://doi.org/10.1097/RLU.0000000000002051
Eshghi, Naghmehossadat, Tamara F. Lundeen, Lea MacKinnon, Ryan Avery, and Phillip H. Kuo. “18F-FDG PET/CT for Monitoring Response of Merkel Cell Carcinoma to the Novel Programmed Cell Death Ligand 1 Inhibitor Avelumab.” Clin Nucl Med 43, no. 5 (May 2018): e142–44. https://doi.org/10.1097/RLU.0000000000002051.
Eshghi N, Lundeen TF, MacKinnon L, Avery R, Kuo PH. 18F-FDG PET/CT for Monitoring Response of Merkel Cell Carcinoma to the Novel Programmed Cell Death Ligand 1 Inhibitor Avelumab. Clin Nucl Med. 2018 May;43(5):e142–4.
Eshghi, Naghmehossadat, et al. “18F-FDG PET/CT for Monitoring Response of Merkel Cell Carcinoma to the Novel Programmed Cell Death Ligand 1 Inhibitor Avelumab.” Clin Nucl Med, vol. 43, no. 5, May 2018, pp. e142–44. Pubmed, doi:10.1097/RLU.0000000000002051.
Eshghi N, Lundeen TF, MacKinnon L, Avery R, Kuo PH. 18F-FDG PET/CT for Monitoring Response of Merkel Cell Carcinoma to the Novel Programmed Cell Death Ligand 1 Inhibitor Avelumab. Clin Nucl Med. 2018 May;43(5):e142–e144.
Published In
Clin Nucl Med
DOI
EISSN
1536-0229
Publication Date
May 2018
Volume
43
Issue
5
Start / End Page
e142 / e144
Location
United States
Related Subject Headings
- Skin Neoplasms
- Radiopharmaceuticals
- Positron Emission Tomography Computed Tomography
- Nuclear Medicine & Medical Imaging
- Male
- Humans
- Fluorodeoxyglucose F18
- Carcinoma, Merkel Cell
- Antineoplastic Agents
- Antibodies, Monoclonal, Humanized